Otsuka makes pipeline changes; Oculis reveals $100M offering
Plus, news about Aardvark’s IPO:
Otsuka cuts cancer programs: The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
